The TCGA Cancer Genome Characterization Center at MSKCC

Information

  • Research Project
  • 7498565
  • ApplicationId
    7498565
  • Core Project Number
    U24CA126543
  • Full Project Number
    5U24CA126543-03
  • Serial Number
    126543
  • FOA Number
    RFA-CA-07-14
  • Sub Project Id
  • Project Start Date
    9/28/2006 - 18 years ago
  • Project End Date
    8/31/2010 - 14 years ago
  • Program Officer Name
    VOCKLEY, JOSEPH G
  • Budget Start Date
    9/1/2008 - 16 years ago
  • Budget End Date
    8/31/2010 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/25/2008 - 16 years ago

The TCGA Cancer Genome Characterization Center at MSKCC

[unreadable] DESCRIPTION (provided by applicant): The TCGA Cancer Genome Characterization Center at MSKCC (designated herein MSK-CGCC) will provide comprehensive profiling of gene expression (whole transcript, exon-level, and microRNA) and of genomic gains and losses (whole genome, and high resolution cancer gene-centered) and will perform high level bioinformatic analyses to identify candidate genes for resequencing by the TCGA Genome Sequencing Centers and novel candidate intergenic rearrangements. Specifically, the MSK-CGCC will meet the three objectives of the RFA as follows: Objective 1: Application of established comprehensive high-throughput technologies. We will perform gene expression profiling on the current Affymetrix U133 Plus arrays and profiling of gains and losses on Agilent 244k CGH arrays. Given the already high capacity of our microarray facility, the MSK-CGCC will be ready to proceed immediately with the expected first year throughput of 1000 samples in this objective. Objective 2: Improve performance of large-scale genomic characterization platforms. These standard platforms will be extended by enhancement of genome coverage and detection of additional types of genomic alterations. Thus, Affymetrix U133 Plus arrays will be extended by the implementation, following careful evaluation and validation, of the new Affymetrix Exon arrays (that will provide data on aberrant splicing patterns and translocation fusion transcripts) and by the use of Agilent microRNA arrays, the latter to be enhanced in successive years by updated designs based on the most comprehensive library of human microRNAs assembled to date. The Agilent 244k CGH arrays will be extended by the design of a complementary custom Agilent array based on a cancer gene-centered tiling strategy optimally suited for the detection of gene fusions associated with gains or losses. Objective 3: Establish cohesive analysis and data mining tools. The MSK-CGCC bioinformatics team will use state-of-the-art methods for raw data processing and quality control to ensure that all released data are well validated. They will also perform a variety of higher level analyses and integrated analyses to derive prioritized lists of genes and genomic regions of interest for sequencing by the TCGA Genome Sequencing Centers. [unreadable] [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U24
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    1503065
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:1503065\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SLOAN-KETTERING INSTITUTE FOR CANCER RES
  • Organization Department
  • Organization DUNS
    064931884
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    10065
  • Organization District
    UNITED STATES